#8 - Johnson & Johnson (NYSE:JNJ)
To get excited about Johnson & Johnson (NYSE:JNJ) stock you have to look away from the short term news. Over the last two years, two major lawsuits have made the company’s stock more volatile than usual. However, the company has been resilient. First, the company recently posted a solid earnings report that calmed investors. And second, the company is one of several companies on the forefront of the ongoing race to develop a vaccine for the Covid-19 virus (aka: coronavirus).
Over the last five years, the company’s stock is up over 35%. And remember, this is a presentation about stocks you can buy and hold for a long time, so you’re looking for proven performance over time. You’re also looking for value. Brand Finance ranked Johnson & Johnson as the most valuable pharma company for 2020. The company is currently worth $10.9 billion.
And if the company provides a nice dividend as a bonus, that’s even better. Johnson & Johnson is a Dividend King, which means they have a 50 year history of increasing its dividend. Prior to 2020, the company had increased its dividend for 57 years and counting.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More - Current Price
- $155.40
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 8 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $175.94 (13.2% Upside)
